Hikma Pharmaceuticals backs outlook as Middle East demand stays robust
Hikma Pharmaceuticals PLC on Thursday reiterated full year guidance following an ‘encouraging’ start to the year, with all three businesses ‘performing well’.
Chief Executive Said Darwazah said: ‘We are pleased with the performance of the group and are on track to deliver revenue and profit growth, in line with our full year guidance.’
Hikma continues to expect revenue to grow between 2% to 4% in 2026, and for operating profit to be in the range of $720 million to $770 million.
In 2025, Hikma reported sales of $3.35 billion, operating profit of $542 million and core operating profit of $741 million.
In a trading statement, the London-based pharmaceuticals firm said its global Injectables business has started the year well and is seeing good demand across geographies.
Hikma continues to expect 2026 Injectables revenue to grow in the low single digits, with core operating margin in the range of 27% to 28%.
The Branded business continues to perform ‘very well’, and Hikma continues to expect annual revenue to grow in the range of 6% to 8%, with core operating margin of around 25%.
Hikma Rx is performing in line with expectations with flat annual revenue projected, unchanged, with core operating margin close to 20%.
Hikma said it is ‘monitoring’ the Middle East crisis but said demand in the region remains ‘robust’.
Interim results for the six months ended June will be published on August 6.
Shares in Hikma were 4.1% higher at 1,376.50 pence each in London on Thursday.
Copyright 2026 Alliance News Ltd. All Rights Reserved.